AUTHORS
Wenjing Guo, PhD, Linlin Liu2, Jia Li3, Erlie Jiang, MD4, Zhijian Xiao5, Sizhou Feng, PhD6
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Introduction: Hypoplastic myelodysplastic neoplasms (MDS-h) and MDS with low blasts (MDS-LB) generally have favorable outcomes, yet the prognostic impact of transfusion dependence (TD) and the survival benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear, particularly in patients who are initially transfusion-independent (TI).
Methods: We retrospectively analyzed 146 patients with MDS-h and 490 with MDS-LB diagnosed according to the World Health Organization (WHO) 2022 criteria at our hospital between June 2016 and June 2024. The prognostic impact of allo-HSCT was evaluated using landmark analyses and time-dependent approaches.
Results: With a median follow-up of 38.9 months (95% CI: 35.7-42.8), 112 patients underwent allo-HSCT. Overall, 69.2% of patients harbored at least one mutation, most frequently U2AF1 (27.3%), ASXL1 (24.1%), and RUNX1 (10.6%). At diagnosis, 42.4% (268/632) of patients were TD. TD was associated with inferior survival irrespective of IPSS-M risk category (5-year OS: TD+IPSS-M HR: 39.1%, TD+IPSS-M LR: 49.4%, TI: 75.6%), and this adverse impact persisted in landmark analyses.
Among initially TI patients, the cumulative incidence of TD development reached 45.6%, with most conversions occurring within the first two years. IPSS-M higher-risk status (HR=2.413, 95% CI: 1.486-3.917, P<0.001) and MDS-LB (HR=2.202, 95% CI: 1.155-4.201, P=0.017) were associated with an increased risk of TD development.
In TD patients, allo-HSCT (n=66) conferred long-term survival benefit (HR=0.513, 95% CI:0.297-0.886, P=0.017), with a 5-year OS of 87.6% versus 48.9% in non-transplanted patients in the 12-month landmark analysis (P<0.001).
Among initially TI patients (n=364), a prognostic model incorporating RUNX1, U2AF1, del(7/7q), bone marrow blasts ≥2% and age>65 years provided additional risk discrimination beyond IPSS-M (C-index: 0.739 vs. 0.651). In TI patients harboring one of these adverse factors (excluding age), allo-HSCT was associated with improved survival in an 18-month landmark analysis (100.00% vs 73.71%, P=0.038).
Conclusions: TD represents a dynamic marker of adverse prognosis and identifies patients most likely to benefit from allo-HSCT. In initially TI patients, adverse biological features, including ≥2% bone marrow blasts, U2AF1 or RUNX1 mutations, and del(7/7q), may help identify candidates who could benefit from transplantation. These findings support a more individualized transplantation strategy integrating transfusion status and disease biology in MDS-h and MDS-LB.
DISCLOSURES
Wenjing Guo, PhD: No relevant conflicts of interest to declare.